Back to Search
Start Over
Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
- Source :
-
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2364519. Date of Electronic Publication: 2024 Jun 16. - Publication Year :
- 2024
-
Abstract
- Mucosal immunity plays a crucial role in combating and controlling the spread of highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant subunit vaccines have shown safety and efficacy in clinical trials, but further investigation is necessary to evaluate their feasibility as mucosal vaccines. This study developed a SARS-CoV-2 mucosal vaccine using spike (S) proteins from a prototype strain and the omicron variant, along with a cationic chitosan adjuvant, and systematically evaluated its immunogenicity after both primary and booster immunization in mice. Primary immunization through intraperitoneal and intranasal administration of the S protein elicited cross-reactive antibodies against prototype strains, as well as delta and omicron variants, with particularly strong effects observed after mucosal vaccination. In the context of booster immunization following primary immunization with inactivated vaccines, the omicron-based S protein mucosal vaccine resulted in a broader and more robust neutralizing antibody response in both serum and respiratory mucosa compared to the prototype vaccine, enhancing protection against different variants. These findings indicate that mucosal vaccination with the S protein has the potential to trigger a broader and stronger antibody response during primary and booster immunization, making it a promising strategy against respiratory pathogens.
- Subjects :
- Animals
Mice
Female
Immunity, Mucosal
Immunogenicity, Vaccine
Cross Reactions immunology
Chitosan immunology
Chitosan administration & dosage
Adjuvants, Vaccine administration & dosage
Vaccines, Inactivated immunology
Vaccines, Inactivated administration & dosage
Spike Glycoprotein, Coronavirus immunology
Administration, Intranasal
Immunization, Secondary methods
COVID-19 Vaccines immunology
COVID-19 Vaccines administration & dosage
Antibodies, Neutralizing blood
Antibodies, Neutralizing immunology
Antibodies, Viral blood
Antibodies, Viral immunology
SARS-CoV-2 immunology
COVID-19 prevention & control
COVID-19 immunology
Mice, Inbred BALB C
Subjects
Details
- Language :
- English
- ISSN :
- 2164-554X
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Human vaccines & immunotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 38880868
- Full Text :
- https://doi.org/10.1080/21645515.2024.2364519